Exploring the Anti‐Tubercular Potential of 2‐(1 H ‐Pyrazol‐1‐yl) Pyrimidine: Design, Synthesis, Biological Evaluation and Molecular Docking Studies
Chemistry & Biodiversity · 2025
DOI: 10.1002/cbdv.202500321 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2025. Verfasst von Mahesh Kumar Talamadla und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Hyderabad, Telangana, India. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Mycobacterium tuberculosis, Antitubercular Agents, Pyrimidines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
We designed and synthesised pyrazolyl pyrimidine‐containing derivatives and screened for anti‐mycobacterial activity. Key intermediate 4‐chloro‐2‐(3,5‐dimethyl‐1H‐pyrazol‐1‐yl)‐6‐methyl pyrimidine is prepared via the literature‐reported protocol. From this intermediate, the two sets of final compounds were prepared. Different spectral techniques like HRMS, 1 H, and 13 C NMR are deployed for the structural confirmation of final derivatives. Final compounds were screened against the Mycobacterium tuberculosis H37Rv strain. Using microplate alamar blue assay, the concentration of compound required to inhibit bacterial growth was assessed. Rifampicin was used as a standard, whose minimum inhibitory concentration (MIC) is 3.12 µg/mL. MIC values of the synthesised compounds varied from 6.25 to 25 µg/mL. Three derivatives, F‐2 , F‐5 and F‐9 among the synthesised, are most active with MIC values of 6.25 µg/mL. F‐2 , F‐5 and F‐9 compounds were also screened for their cytotoxicity against normal cells, where F‐9 has shown selectivity over normal human embryonic kidney cell lines (HEK293T). In silico ADME was evaluated using the SWISS ADME tool. Docking studies were carried out for F‐2 , F‐5 and F‐9 at the active site of InhA (PDB ID: 4TZK), the enoyl acyl carrier protein reductase. MD simulations were carried out for F‐9 to assess the stability of the protein–ligand complex.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Hyderabad, Telangana, India.
- College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh, India.
- Medicinal Chemistry Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Pilani, Rajasthan, India.
ORCID-Profile: Mahesh Kumar Talamadla, Adinarayana Nandikolla, Kondapalli Venkata Gowri Chandra Sekhar
Zitieren
APA
Talamadla, M. K., Nandikolla, A., Shobha, S., Nayar, P. P., Kumar, M. M. K., Sankaranarayanan, M., & Sekhar, K. V. G. C. (2025). Exploring the Anti‐Tubercular Potential of 2‐(1 H ‐Pyrazol‐1‐yl) Pyrimidine: Design, Synthesis, Biological Evaluation and Molecular Docking Studies. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202500321
Vancouver
Talamadla MK, Nandikolla A, Shobha S, Nayar PP, Kumar MMK, Sankaranarayanan M, et al. Exploring the Anti‐Tubercular Potential of 2‐(1 H ‐Pyrazol‐1‐yl) Pyrimidine: Design, Synthesis, Biological Evaluation and Molecular Docking Studies. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202500321
BibTeX
@article{Talamadla2025,
author = {Talamadla, Mahesh Kumar and Nandikolla, Adinarayana and Shobha, Singarapalle and Nayar, Pranav Pramod and Kumar, Muthyala Murali Krishna and Sankaranarayanan, Murugesan and Sekhar, Kondapalli Venkata Gowri Chandra},
title = {Exploring the Anti‐Tubercular Potential of 2‐(1 H ‐Pyrazol‐1‐yl) Pyrimidine: Design, Synthesis, Biological Evaluation and Molecular Docking Studies},
journal = {Chemistry & Biodiversity},
year = {2025},
doi = {10.1002/cbdv.202500321}
}
EUVIMED